Stifel Reiterates Buy on Mirum Pharmaceuticals, Maintains $48 Price Target
Stifel Reiterates Buy on Mirum Pharmaceuticals, Maintains $48 Price Target
Stifel重申Mirum Pharmaceuticals買入評級，維持48美元的目標價。
Stifel analyst Dae Gon Ha reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $48 price target.
Stifel分析師Dae Gon Ha重申對mirum pharmaceuticals (NASDAQ: MIRM)的買入評級，並將其維持在48美元的目標價位。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。